Overview

  • Product nameAnti-RED1 antibody
    See all RED1 primary antibodies
  • Description
    Rabbit polyclonal to RED1
  • Tested applicationsSuitable for: ELISA, WB, ICC/IF, IHC-Pmore details
  • Species reactivity
    Reacts with: Mouse, Human
    Predicted to work with: Rat
  • Immunogen

    Synthetic peptide derived from an internal sequence of human RED1.

  • Positive control
    • HepG2 cell extracts.

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
  • Storage bufferPreservative: 0.02% Sodium Azide
    Constituents: 50% Glycerol, PBS, 150mM Sodium chloride, pH 7.4
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab64830 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA 1/20000.
WB 1/500 - 1/1000. Detects a band of approximately 81 kDa (predicted molecular weight: 81 kDa).
ICC/IF Use a concentration of 1 - 5 µg/ml.
IHC-P 1/200. PubMed: 24608178

Target

  • FunctionCatalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor (GABRA3) and potassium voltage-gated channel (KCNA1). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alter their functional activities. Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently. Can exert a proviral effect towards human immunodeficiency virus type 1 (HIV-1) and enhances its replication via both an editing-dependent and editing-independent mechanism. The former involves editing of adenosines in the 5'UTR while the latter occurs via suppression of EIF2AK2/PKR activation and function. Can inhibit cell proliferation and migration and can stimulate exocytosis.
  • Tissue specificityHighly expressed in brain and heart and at lower levels in placenta. Fair expression in lung, liver and kidney. Detected in brain, heart, kidney, lung and liver (at protein level). Isoform 5 is high expressed in hippocampus and colon. Isoform 5 is expressed in pediatric astrocytomas and the protein has a decreased RNA-editing activity. The decrease in RNA editing correlates with the grade of malignancy of the tumors, with the high grade tumors showing lower editing is seen.
  • Sequence similaritiesContains 1 A to I editase domain.
    Contains 2 DRBM (double-stranded RNA-binding) domains.
  • Cellular localizationNucleus. Nucleus > nucleolus. Shuttles between nucleoli and the nucleoplasm.
  • Information by UniProt
  • Database links
  • Alternative names
    • ADARB 1 antibody
    • ADARB1 antibody
    • 1700057H01Rik antibody
    • ADAR2 antibody
    • ADAR2a antibody
    • ADAR2a L1 antibody
    • ADAR2a L2 antibody
    • ADAR2a L3 antibody
    • ADAR2b antibody
    • ADAR2c antibody
    • ADAR2d antibody
    • ADAR2g antibody
    • Adarb1 antibody
    • Adenosine deaminase, RNA specific, 2 antibody
    • Adenosine deaminase, RNA specific, B1 (homolog of rat RED1) antibody
    • Adenosine deaminase, RNA specific, B1 (RED1 homolog rat) antibody
    • Adenosine deaminase, RNA specific, B1 antibody
    • AW124433 antibody
    • AW558573 antibody
    • BB220382 antibody
    • D10Bwg0447e antibody
    • Double stranded RNA specific editase 1 antibody
    • Double-stranded RNA-specific editase 1 antibody
    • DRABA2 antibody
    • DRADA2 antibody
    • dsRNA adenosine deaminase antibody
    • EC 3.5.-.- antibody
    • Human dsRNA adenosine deaminase DRADA2 antibody
    • Human dsRNA adenosine deaminase DRADA2b, EC 3.5 antibody
    • OTTHUMP00000115341 antibody
    • OTTHUMP00000115342 antibody
    • RED 1 antibody
    • RED1_HUMAN antibody
    • RNA editase antibody
    • RNA editase 1 antibody
    • RNA editing deaminase 1 antibody
    • RNA editing enzyme 1 antibody
    • RNA editing enzyme 1, rat, homolog of antibody
    • RNA specific adenosine deaminase B1 antibody
    • RNA-editing deaminase 1 antibody
    • RNA-editing enzyme 1 antibody
    see all

Anti-RED1 antibody images

  • All lanes : Anti-RED1 antibody (ab64830) at 1/500 dilution

    Lane 1 : HepG2 cell extract (5-30 µg total protein)
    Lane 2 : HepG2 cell extract (5-30 µg total protein) ) with 5-10 µg of the immunising peptide


    Predicted band size : 81 kDa
    Observed band size : 81 kDa
  • ICC/IF image of ab64830 stained HeLa cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab64830, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

References for Anti-RED1 antibody (ab64830)

This product has been referenced in:
  • Wang AL  et al. Down-regulation of the RNA editing enzyme ADAR2 contributes to RGC death in a mouse model of glaucoma. PLoS One 9:e91288 (2014). IHC-P ; Mouse . Read more (PubMed: 24608178) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab64830.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"